---
schema_version: "secwatch.filing_event.v1"
accession: "0001658247-26-000011"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:39:47.202875+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Crinetics Q4 2025: Palsonify launch revenue $5.4M, net loss $122.8M; EU CHMP positive opinion

## Summary
- PALSONIFY net product revenue $5.4M in Q4 2025; >200 enrollment forms by Dec end; 125+ HCPs prescribed in Q4.
- CHMP adopted positive opinion recommending EU marketing authorization for paltusotine in acromegaly; EC decision pending.
- Seamless Phase 2/3 EQUILIBRIUM study of atumelnant in Cushing's syndrome to start H1 2026; Phase 3 trials for CAH and carcinoid syndrome initiated.
- Full-year 2025 net loss $465.3M; cash used $326.2M, below guidance; cash $1.0B at Dec 31, 2025 (pro forma $1.4B post Jan 2026 offering).
- 2026 GAAP OpEx guidance $600-650M; non-GAAP OpEx $480-520M; R&D and SG&A investments continue.

## SEC filing metadata
- accession: 0001658247-26-000011
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000011/0001658247-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000011/crnx-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001658247-26-000011
- JSON: https://secwatch.observer/filing/0001658247-26-000011.json
- Plain text: https://secwatch.observer/filing/0001658247-26-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.